IRI Separation Technologies Inc.

IRI Separation Technologies Inc.

March 04, 2008 09:00 ET

IRI Separation Technologies Inc. Announces Update on Regulatory Progress Toward NHP

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 4, 2008) - IRI Separation Technologies Inc. (TSX VENTURE:IRI) IRI Separation Technologies Inc. has filed a number of applications to NHP over the past months and has now received the first confirmation of a submission by way of receipt, of a Natural Health Product Submission Number. Other receipts are expected in the near future.

"IRI personnel have worked diligently in order to achieve a product acceptable for sale into the market. The receipt of this submission number is a significant milestone in a long journey from the first bench top test, through to the pilot plant, to scaled production and finally a finished product and its associated NHP submission," said Rick Stiksma President and CEO.

About IRI Separation Technologies Inc.

IRI Separation Technologies Inc. (TSX VENTURE:IRI) is a biotechnology company that specializes in the extraction, development and commercialization of polyclonal immunoglobulin antibodies for virus and bacteria related health issues. Intended for use as a nutraceutical for human consumption, the antibodies are derived from chicken eggs. The immunoglobulin antibodies are intended for both the general and specific antibody market.

On behalf of the Board of Directors, John Mason, Chairman.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information